Changeflow GovPing Healthcare & Life Sciences Norway RMS DCP Slots Fully Allocated for 2026
Routine Notice Added Final

Norway RMS DCP Slots Fully Allocated for 2026

Favicon for www.dmp.no Norway NOMA News alt
Published
Detected
Email

Summary

The Norwegian Medical Products Agency (NOMA) has announced that all Reference Member State (RMS) slots for decentralised procedure (DCP) assessment of human medicinal products for 2026 have been fully allocated. Requests received after 5 March 2026 will not be considered. Exceptions may be made for medicinal products of significant public health importance, particularly those on the announced list of needed products. NOMA will begin accepting requests for 2027 RMS DCP slots from the fourth quarter of 2026. This notice does not apply to veterinary DCP applications.

“Requests received after 5 March 2026 will not be considered by NOMA.”

NOMA , verbatim from source
Published by NOMA on dmp.no . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors Norway NOMA News alt for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

NOMA has announced the closure of its RMS DCP slot allocation process for 2026 due to full capacity. All requests submitted after 5 March 2026 are ineligible and will not be processed under normal procedures. Pharmaceutical companies and marketing authorisation applicants seeking Norway as RMS for human medicinal products should note that exceptions may apply for products of significant public health importance, including those on NOMA's announced list of needed products. Applicants should contact NOMA directly for such exceptions. Planning for 2027 submissions can begin from Q4 2026, when NOMA will publish information on its website regarding new slot availability.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Requests for Norway as RMS in the assessment of human medicinal products in the Decentralised Procedure – 2026

Published:

06/03/2026

Changes

Close The Norwegian Medical Products Agency (NOMA) has no available slots for RMS in decentralised procedure (DCP); all positions for 2026 have now been allocated. Requests received after 5 March 2026 will not be considered by NOMA.

NOMA may make exceptions for medicinal products of significant importance to public health. This particularly applies to medicinal products announced in the list of needed products. In such cases, applicants are encouraged to contact NOMA.

From the fourth quarter of 2026, it will be possible to submit requests for RMS DCP slots for 2027. More information will be published on NOMA’s website.

This information does not apply to veterinary DCP applications.

See more news

Approval of medicines

Contact us

Unit for regulatory affairs before MA

(+47) 22 89 77 00

mt@noma.no

Print

Did you find what you were looking for?

Describe what you did not find

0/255 characters

I confirm that I do not submit any personal information, e.g. name, telephone number or email address. Cancel

Get daily alerts for Norway NOMA News alt

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NOMA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NOMA
Published
March 6th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Marketing authorisation Regulatory submission
Geographic scope
NO NO

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Regulatory Affairs

Get alerts for this source

We'll email you when Norway NOMA News alt publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!